



 [Update Your Profile](#)

Simeon I. Taylor, MD, PhD

Academic Title:

Professor

Primary Appointment:

Medicine

Email:

staylor2@medicine.umaryland.edu

Location:

MSTF, 357B

Phone (Primary):

410-706-6439

[Download CV](#)

Education and Training

- Harvard College, BA, 1969
- Harvard University, PhD, 1974
- Harvard Medical School, MD, 1976
- Residency, Internal Medicine, Massachusetts General Hospital, 1976-78
- Fellowships, Endocrinology & Metabolism, Massachusetts General Hospital, 1978-79; National Institutes of Health Inter-Institute Training Program in Endocrinology, 1979-81

Biosketch

Dr. Simeon Taylor received a B.A. (Chemistry) from Harvard College in 1969, followed by Ph.D. and M.D. degrees from Harvard Medical School in 1974 and 1976, respectively. He completed clinical training in the specialty of Internal Medicine and sub-specialty of Endocrinology & Metabolism at Massachusetts General Hospital (1976-1979) and National

Institutes of Health (1979-1981). He worked in the Intramural Research Program of NIDDK (1979-2000), where he occupied positions of increasing responsibility, including Chief of the Diabetes Branch (1989-2000). His work at NIDDK was recognized by the Outstanding Service Award, United States Public Health Service (1990) and the Outstanding Scientific Achievement Award of the American Diabetes Association (1992). In addition, he served as Director of the NIH Inter-Institute Clinical Training Program in Endocrinology & Metabolism (1995-1998).

He moved to the pharmaceutical industry in 2000: first at Eli Lilly (2000-2002) where he was a Lilly Research Fellow in Endocrine Research and later at Bristol-Myers Squibb where he served as Vice President Cardiovascular & Metabolic Disease Research (2002-2010) and Vice President Research & Scientific Affairs (2010-2013). During his time at Bristol-Myers Squibb, he made substantial contributions to R&D leading to four approved drugs: saxagliptin, dapagliflozin, apixaban, and metreleptin.

He joined the faculty at the University of Maryland School of Medicine in 2013, first as an Adjunct Professor of Medicine (2013-2015) and currently as a Professor of Medicine. In addition, he serves as Director of the Mid-Atlantic Nutrition Obesity Research Center.

Research/Clinical Keywords

Diabetes, endocrinology, metabolism, insulin action, insulin resistance, pharmacology, pharmacogenetics, SGLT2 inhibitors, metreleptin

Highlighted Publications

1. Kadowaki T, Bevins CL, Cama A, Ojamaa K, Marcus-Samuels B, Kadowaki H, Beitz L, McKeon C, **Taylor SI** (1988) Two mutant alleles of the insulin receptor gene in a patient with extreme insulin resistance. *Science*, 240: 787-790
2. **Taylor SI** (1992) 1992 Lilly Lecture. Molecular mechanisms of insulin resistance: lessons from patients with mutations in the insulin receptor gene. *Diabetes*, 41: 1473-1490
3. Arioglu-Oral E, Simha V, Ruiz E, Sebring N, Andewelt A, Premkumar A, Snell P, Wagner A, DePaoli A, Reitman ML, **Taylor SI**, Gorden P, Garg A (2002) Efficacy and safety of leptin replacement in treatment of lipodystrophy. *N Engl J Med*, 346: 570-578
4. **Taylor SI**, Blau JE, Rother KI (2015) Possible adverse effects of SGLT2-inhibitors on bone. *Lancet Diabetes & Endocrinology* 3: 8-10
5. **Taylor, S.I.**, Blau, J.E., Rother, K.I.: SGLT2 inhibitors may predispose to ketoacidosis. *J. Clin. Endocrinol. Metab.*, 100: 2849-2852, 2016

 [Update Your Profile](#)